Literature DB >> 19428722

Engineered affinity proteins--generation and applications.

Caroline Grönwall1, Stefan Ståhl.   

Abstract

The use of combinatorial protein engineering to design proteins with novel binding specificities and desired properties has evolved into a powerful technology, resulting in the recent advances in protein library selection strategies and the emerge of a variety of new engineered affinity proteins. The need for different protein library selection methods is due to that each target protein pose different challenges in terms of its availability and inherent properties. At present, alternative engineered affinity proteins are starting to complement and even challenge the classical immunoglobulins in different applications in biotechnology and potentially also for in vivo use as imaging agents or as biotherapeutics. This review article covers the generation and use of affinity proteins generated through combinatorial protein engineering. The most commonly used selection techniques for isolation of desired variants from large protein libraries are described. Different antibody derivatives, as well as a variety of the most validated engineered protein scaffolds, are discussed. In addition, we provide an overview of some of the major present and future applications for these engineered affinity proteins in biotechnology and medicine.

Mesh:

Substances:

Year:  2009        PMID: 19428722     DOI: 10.1016/j.jbiotec.2009.01.014

Source DB:  PubMed          Journal:  J Biotechnol        ISSN: 0168-1656            Impact factor:   3.307


  20 in total

Review 1.  A mass spectrometry view of stable and transient protein interactions.

Authors:  Hanna G Budayeva; Ileana M Cristea
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

Review 2.  Progress in phage display: evolution of the technique and its application.

Authors:  Tomaz Bratkovic
Journal:  Cell Mol Life Sci       Date:  2010-03       Impact factor: 9.261

3.  Targeting diverse protein-protein interaction interfaces with α/β-peptides derived from the Z-domain scaffold.

Authors:  James W Checco; Dale F Kreitler; Nicole C Thomas; David G Belair; Nicholas J Rettko; William L Murphy; Katrina T Forest; Samuel H Gellman
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-30       Impact factor: 11.205

4.  Positive progress in immunoPET--not just a coincidence.

Authors:  Katelyn E McCabe; Anna M Wu
Journal:  Cancer Biother Radiopharm       Date:  2010-06       Impact factor: 3.099

5.  Iterative Nonproteinogenic Residue Incorporation Yields α/β-Peptides with a Helix-Loop-Helix Tertiary Structure and High Affinity for VEGF.

Authors:  James W Checco; Samuel H Gellman
Journal:  Chembiochem       Date:  2017-01-09       Impact factor: 3.164

Review 6.  SH3 domains come of age.

Authors:  Brian K Kay
Journal:  FEBS Lett       Date:  2012-06-05       Impact factor: 4.124

Review 7.  Peptide aptamers: development and applications.

Authors:  Sergey Reverdatto; David S Burz; Alexander Shekhtman
Journal:  Curr Top Med Chem       Date:  2015       Impact factor: 3.295

Review 8.  Computational design of protein-ligand interfaces: potential in therapeutic development.

Authors:  Andrew Morin; Jens Meiler; Laura S Mizoue
Journal:  Trends Biotechnol       Date:  2011-02-04       Impact factor: 19.536

9.  Molecular bases of cyclodextrin adapter interactions with engineered protein nanopores.

Authors:  Arijit Banerjee; Ellina Mikhailova; Stephen Cheley; Li-Qun Gu; Michelle Montoya; Yasuo Nagaoka; Eric Gouaux; Hagan Bayley
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-16       Impact factor: 11.205

Review 10.  Protease-resistant peptide design-empowering nature's fragile warriors against HIV.

Authors:  Matthew T Weinstock; J Nicholas Francis; Joseph S Redman; Michael S Kay
Journal:  Biopolymers       Date:  2012       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.